國家衛生研究院 NHRI:Item 3990099045/7951
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 912296      Online Users : 1188
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7951


    Title: SLC14A1 down-regulation is associated with poor clinical outcome in patients with urothelial carcinoma of upper urinary tracts and urinary bladder
    Authors: Liang, PI;Li, CF
    Contributors: National Institute of Cancer Research
    Abstract: Background: Urothelial carcinoma (UC) is a common cancer in industrialized country. UC of urinary bladder (UCUB) and of upper urinary tract (UCUT) may share similar tumorigenesis. Previously, genome-wide association studies identifi ed that genetic variation of solute carrier family 14 transporters, member 1 (SLC14A1) is associated with bladder cancer development. By using public domain datasets and our well-characterized cohort, we intended to analyze the association of SLC14A1 expression in UCUB and UCUT.Design: Two datasets from GEO (GSE31684 and GSE32894) were selected and analyzed to examine the signifi cance of SLC14A1 transcript expression in relation to primary tumor (pT) status. SLC14A1 transcript levels were further validated by using Quantigene assay in 35 and 40 UBUC and UTUC cases respectively, and were further correlated with various clincopathological factors. SLC14A1 immunostain was performed on 340 cases of UCUT and 295 cases of UBUC and interpreted by using H-score. The immunoexpression was then correlated with clinicopathological features, disease-specifi c survival (DSS), and metastasis-free survival (MeFS).Results: Validation of SLC14A1 transcript in public domain datasets showed a stepwise down-regulation during UCUB progression, which is also confi rm by using Quantigene assay in our cohort. In the immunohistochemical study, loss of SLC14A1 expression in both groups of UCs signifi cantly associated with advanced pT stage (both p <0.001), lymph node metastasis (both p <0.001), high histological grade (both p <0.001), vascular invasion (both p <0.001), perineurial invasion (UCUT, p =0.002; UCUB, p =0.021), and frequent mitosis (both p =0.003). Loss of SLC14A1 expression also independently predicted poor DSS (UCUT p =0.033; UCUB p =0.005) and MeFS (UCUT p =0.012; UCUB p =0.031) in both groups of patients.Conclusions: SLC14A1 down-regulation is associated with advanced tumor stage and conferred poorer clinical outcome, justifying that SLC14A1 is a potential prognostic biomarker of UC.
    Date: 2014-02
    Relation: Laboratory Investigation. 2014 Feb;94(S1):245A.
    Link to: http://dx.doi.org/10.1038/labinvest.2014.23
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0023-6837&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000331155801225
    Appears in Collections:[Others] Conference Papers/Meeting Abstract

    Files in This Item:

    File Description SizeFormat
    ISI000331155801225.pdf159KbAdobe PDF500View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback